| Company Name: |
MedChemexpress LLC
|
| Tel: |
021-58955995 |
| Email: |
sales@medchemexpress.cn |
| Products Intro: |
Product Name:RISARESTAT
CAS:79714-31-1
Purity:>98% Package:4000RMB/1mg
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Email: |
eric_feng1954@126.com |
| Products Intro: |
Product Name:RISARESTAT
CAS:79714-31-1
Purity:95% -98%HPLC Package:1GR;10GR;50GR;100GR;250GR;500GR;1KG;5KG;10KG;100KG
|
CT 112 manufacturers
- Risarestat
-
- $373.00 / 5mg
-
2025-10-27
- CAS:79714-31-1
- Min. Order:
- Purity: 98.39%
- Supply Ability: 10g
|
| Product Name: | CT 112 | | Synonyms: | 5-(3-Ethoxy-4-pentoxyphenyl)thiazolidine-2,4-dione;5-(3-Ethoxy-4-pentyloxyphenyl)-2,4-thiazolidinedione;5-[3-Ethoxy-4-(pentyloxy)phenyl]-2,4-thiazolidinedione;Risarestat;CT 112 (reductase inhibitor);RISARESTAT (CT-112);2,4-Thiazolidinedione, 5-[3-ethoxy-4-(pentyloxy)phenyl]-;Risarestat, 10 mM in DMSO | | CAS: | 79714-31-1 | | MF: | C16H21NO4S | | MW: | 323.41 | | EINECS: | | | Product Categories: | | | Mol File: | 79714-31-1.mol |  |
| | CT 112 Chemical Properties |
| Boiling point | 485.9±45.0 °C(Predicted) | | density | 1.189±0.06 g/cm3(Predicted) | | pka | 5.91±0.50(Predicted) | | form | Solid | | color | White to light yellow |
| | CT 112 Usage And Synthesis |
| Uses | Risarestat (CT-112), an aldose reductase inhibitor, is developed for the treatment of diabetic complications. | | Definition | ChEBI: Risarestat is a thiazolidinone. | | in vivo | Risarestat inhibits the accumulation of dulcitol in a dose-dependent manner, except for the 1.0% solution which has an activity comparable to the 0.25% solution[1]. Risarestat peaks in the corneal epithelium, stroma, endothelium and aqueous humor in 30 minutes following instillation, then gradually diminishes time-dependently over a period of 24 hours. Risarestat remains detectable in the lens up to 24 hours, with a peak concentration at 2 hours after instillation[2]. The anterior surface area of superficial cells in the group treated with Risarestat is significantly decreases from a mean value of 881 to 728 microns2. Corneal sensitivity significantly improves from 5.36 to 1.37 g/mm2[3]. Animals treated with Risarestat shows a significant increase in the mean blinkresponse compared to untreated galactose-fed rats and does not differ significantly from controls towards the completion of the 7 month study. Animals treated topically with Risarestat and untreated galactose-fed rats develop bilateral nuclear cataracts within 3 weeks[4]. | | References | [1] Awata T, et al. Effect of an aldose reductase inhibitor, CT-112, on healing of the corneal epithelium in galactose-fed rats. J Ocul Pharmacol. 1988 Fall;4(3):195-201. DOI:10.1089/jop.1988.4.195
[2] Ohashi Y, et al. Intraocular penetration of CT-112, an aldose reductase inhibitor, following topical instillation. J Ocul Pharmacol. 1989 Winter;5(4):325-8. DOI:10.1089/jop.1989.5.325
[3] Hosotani H, et al. Reversal of abnormal corneal epithelial cell morphologic characteristics and reduced corneal sensitivity in diabetic patients by aldose reductase inhibitor, CT-112. Am J Ophthalmol. 1995 Mar;119(3):288-94. DOI:10.1016/s0002-9394(14)71169-9
[4] Jacot JL, et al. Diabetic-like corneal sensitivity loss in galactose-fed rats ameliorated with aldose reductase inhibitors. J Ocul Pharmacol Ther. 1998 Apr;14(2):169-80. DOI:10.1089/jop.1998.14.169 |
| | CT 112 Preparation Products And Raw materials |
|